




Miranda

Age 58

After an initial response to UDCA, Miranda is showing signs of disease progression with rising ALP levels at 10 years post-diagnosis.

ALP¹



Bilirubin²

0.8 mg/dL (0.7 x ULN)
at diagnosis



1.1 mg/dL (0.9 x ULN)
currently

Time since diagnosis: 10 years

Symptoms: Brain fog

Current treatment: UDCA 850 mg daily
(15 mg/kg/day)

Time on treatment: 10 years on UDCA



Does a progressive rise in ALP levels warrant a reassessment of treatment goals for Miranda?


Miranda shows signs of progression after long-term response to treatment

Lower ALP levels are associated with improved survival³

Survival rates in patients with normalized ALP were 8% higher than those with ALP 1.67-3.0 x ULN.³

Treatment goals should be continually reassessed for all patients with PBC, including those previously stable on therapy.^{3,4}

Outcomes stratified by ALP levels in patients with normal bilirubin at one year³



Adapted with permission from Wolters Kluwer Health, Inc.: Murillo Perez CF, et al; Global PBC Study Group. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. *Am J Gastroenterol.* 115(7):1066-1074, suppl. https://journals.lww.com/ajg/abstract/2020/07000/goals_of_treatment_for_improved_survival_in.20.aspx

ALP=alkaline phosphatase; PBC=primary biliary cholangitis; UDCA=ursodeoxycholic acid; ULN=upper limit of normal.

References: 1. ALKI. Mayo Clinic Laboratories. Accessed February 24, 2024. <https://www.mayocliniclabs.com/test-catalog/overview/89503#Clinical-and-Interpretive> 2. BILI3. Mayo Clinic Laboratories. Accessed February 24, 2024. <https://www.mayocliniclabs.com/test-catalog/overview/8452#Clinical-and-Interpretive> 3. Murillo Perez CF, Harms MH, Lindor KD, et al; Global PBC Study Group. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. *Am J Gastroenterol.* 2020;115(7):1066-1074, suppl. 4. Kowdley KV, Bowls CL, Levy C, et al. Application of the latest advances in evidence-based medicine in primary biliary cholangitis. *Am J Gastroenterol.* 2023;118(2):232-242.